Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?
Immunovant (IMVT) Upgraded to Buy: Here's What You Should Know
Truist Securities Maintains Hold on Immunovant, Raises Price Target to $33
Wells Fargo Maintains Overweight on Immunovant, Raises Price Target to $47
Immunovant (IMVT) Q2 2027 Earnings Call Transcript
Immunovant, Inc. Q2 2027 Earnings Call Summary
Immunovant Stock What Changed After Arthritis Trial Success
Immunovant, Inc. (IMVT) Q2 2027 Earnings Call Transcript
What Immunovant (IMVT) Said on Its Q2 Earnings Call
Immunovant surges on trial results, earnings beat
Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study
Immunovant Files Prospectus For Offering Mixed Shelf; Terms Undisclosed
Immunovant (IMVT) Stock Looks Stretched On Book Value Alone
Immunovant: Batoclimab 2.0 Bull Case Flawed By Mixed Data, Competitive Threats
Immunovant Q1 2027 Earnings Call: Complete Transcript
Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's Next
Immunovant (IMVT) Just Gave Investors Something To Think About
Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case
Roivant reports top-line data from IMVT-1402 CLE trial
Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.